Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose furmonertinib plus chemotherapy as first-line treatment for EGFR-mutant NSCLC with CNS metastases
ChiCTR2400084196Phase 2Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib, pemetrexed and carboplatin in non-small cell lung cancer (NSCLC) and central nervous system metastases, sponsored by Anhui Provincial Tumor Hospital. Primary endpoint: Progression-free survival. Planned start May 2024; status: not yet recruiting.
02
Drugs
furmonertinibpemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)central nervous system metastases
Beyond the preview
Go deeper on ChiCTR2400084196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084196.